A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gerard Kennealey, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
106 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
La Roche-sur-Yon, France
- Facility name not stated
Paris, France
- Facility name not stated
Alba, Italy
- Facility name not stated
Fano, Italy
- Facility name not stated
Foggia, Italy
- Facility name not stated
Lecco, Italy
- Facility name not stated
Milan, Italy
- Facility name not stated
Naples, Italy
- Facility name not stated
Pontedera, Italy
- Facility name not stated
Roma, Italy
- Facility name not stated
Saronno, Italy
- Facility name not stated
Lisbon, Portugal
- Facility name not stated
A Coruña, Spain
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Jaén, Spain
- Facility name not stated
Lleida, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Cardiff, United Kingdom
- Facility name not stated
Glasgow, United Kingdom
- Facility name not stated
Kingston upon Thames, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Nottingham, United Kingdom
- Facility name not stated
Sutton, United Kingdom
- Facility name not stated
Taunton, United Kingdom
- Facility name not stated
Truro, United Kingdom
- Facility name not stated
Yeovil, United Kingdom
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Chandler, Arizona, United States
- Facility name not stated
Sedona, Arizona, United States
- Facility name not stated
La Jolla, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Oxnard, California, United States
- Facility name not stated
San Diego, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
Santa Monica, California, United States
- Facility name not stated
Aurora, Colorado, United States
- Facility name not stated
Denver, Colorado, United States
- Facility name not stated
New Haven, Connecticut, United States
- Facility name not stated
Washington D.C., District of Columbia, United States
- Facility name not stated
Fort Myers, Florida, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2014
- Primary completion
- 29 Feb 2016
- Completion
- 31 Jan 2017
- Last update posted
- 13 Feb 2018
- Registered enrollment
- 149
- Registry id
- NCT02120417
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.